#United States #St. Paul #Solventum #NYSE SOLV #Q2 Financial Results

Solventum Reports Strong Financial Performance for Q2 2025

St. Paul, Minnesota – August 7, 2025 – Solventum (NYSE: SOLV) has unveiled its financial results for the second quarter ended June 30, 2025, revealing a robust increase in sales and an optimistic outlook for the remainder of the year. This marks a significant turn for the company, aligning with its strategic transformation efforts aimed at enhancing business performance.

Financial Highlights

In the second quarter, Solventum reported net sales amounting to $2.2 billion, showcasing an impressive 3.9% increase compared to the same period last year. When adjusted for organic growth, the sales increased by 2.8%. Furthermore, the company recorded GAAP diluted earnings per share (EPS) of $0.51 and an adjusted diluted EPS of $1.69, reflecting a 8.3% increase year on year. Operating cash flow also stood positively at $169 million, with a free cash flow of $59 million.

CEO Bryan Hanson expressed satisfaction with the results, stating, “Our solid second quarter fiscal year 2025 results mark five consecutive quarters of positive sales volume growth since implementing our transformation strategy. Given the continued and underlying momentum in our business and markets, we have raised our full year 2025 guidance at both the top and bottom line, reflecting confidence in our strategy and execution.”

Segment Performance

The organic sales growth was primarily driven by strong performances across all segments, with MedSurg and Health Information Systems (HIS) leading the way. For details, here is a closer look at net sales by segment for the second quarter:

• - Advanced Wound Care: $467 million (up 1.7%)
• - Infection Prevention and Surgical Solutions: $750 million (up 6.9%)
• - MedSurg: $1,218 million (up 4.8%)
• - Dental Solutions: $338 million (up 2.3%)
• - Health Information Systems: $339 million (up 3.4%)
• - Purification and Filtration: $252 million (up 5.4%)

These figures illustrate a well-rounded performance across Solventum's diverse product lines, underscoring their commitment to fostering healthcare innovations.

Outlook for 2025

In light of the strong Q2 results, Solventum has revised its full-year earnings guidance upwards. The company now anticipates organic sales growth will range between 2.0% and 3.0%. The adjusted EPS outlook has also been raised to between $5.80 to $5.95, reflecting a strategic aim to capitalize on positive business trends. Moreover, Solventum expects free cash flow to remain stable in the range of $450 million to $550 million.

Hanson's optimism is clear as he emphasized the company's strategy and execution in adapting to market conditions. This forecast revision signals confidence in both the operational capabilities and the strategic direction of Solventum as it continues to innovate and expand in the healthcare sector.

Conclusion

Solventum's Q2 2025 financial results clearly demonstrate strong growth across vital segments and a solid outlook, indicating the successful implementation of its long-term strategic initiatives. The commitment to enhancing healthcare delivery remains at the forefront as the company persistently adapts to the evolving landscape while driving stakeholder value. Investors and market watchers will keenly observe how Solventum capitalizes on this positive trajectory in the upcoming quarters.